You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. REPLIMUNE GROUP INC

Replimune Group Inc XNAS: REPL

Replimune Group Inc Live Share Price Today, Share Analysis and Chart

Download real time

8.76 0.76 (9.50%)

48.47% Fall from 52W High

1.3M XNAS Volume

XNAS 21 Apr, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share

Replimune Group Inc Key Metrics

Select

Market Capitalization

Below industry Median
674.6

PE TTM

Negative PE TTM
-3

PEG TTM

High in industry
0.3

Price to Book

Below industry Median
1.4

Institutional holding current Qtr %

High in industry
103.4

Net Profit Qtr Growth YoY %

Negative Net Profit Qtr Growth YoY %
-29.8

Net Profit TTM Growth %

Negative Net Profit TTM Growth %
-8.7

Rel Perf vs Sector quarter%

-13

ROE Annual %

Negative ROE Annual %
-46.4

RoA Annual %

Negative RoA Annual %
-38
All financials are in USD Million and price data in USD
VIEW MORE
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
9.0 / 100
Momentum Score
Technically Neutral
37.6 / 100
Analyst Price Target
No estimates available

13

S

11

W

5

O

0

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Replimune Group Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Replimune Group Inc Stock Analysis

Replimune Group Inc stock analysis with key metrics, changes, and trends.

Replimune Group Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$215.79 M23.82%negative

Annual Net Profit fell 23.82% in the last year to $215.79 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio-2.96-negative

Price to Earning Ratio is -2.96, which is negative.

Stock Price$8.7635.81%positive

Stock Price rose 35.81% and outperformed its sector by 29% in the past year.

Quarterly Net profit$66.34 M29.77%negative

Quarterly Net profit fell 29.77% YoY to $66.34 M. Its sector's average net profit growth YoY for the quarter was -41.98%.

Debt to Equity Ratio0.2-positive

Debt to Equity Ratio of 0.2 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)-46.42 %-46.42%negative

Return on Equity(ROE) for the last financial year was -46.42%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding51.53 %1.29%positive

Mutual Fund Holding increased by 1.29% in the last quarter to 51.53.

Promoter Share Holding6.32 %0.91%positive

Promoter Share Holding increased by 0.91% in the most recent quarter to 6.32%.

Interest Coverage Ratio-31.34-negative

Interest Coverage Ratio is -31.34, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding103.38 %0.01%positive

Institutional Holding increased by 0.01% in the last quarter to 103.38.

VIEW LESS


Loading data..

Replimune Group Inc - Company Profile

What does Replimune Group Inc do?

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group Inc Management structure

All Gross Remunerations are in USD
Dr. Robert Coffin, PhD
Director and Chief Scientist
-
2025
Gross Remuneration
Year

Replimune Group Inc Board of directors

All Gross Remunerations are in USD
Dr. Hyam I. Levitsky,M.D.
Independent Director
-
2025
Gross Remuneration
Year
Mr. Madhavan Balachandran
Independent Director
-
2025
Gross Remuneration
Year
Dr. Robert Coffin, PhD
Director and Chief Scientist
-
2025
Gross Remuneration
Year
Mr. Michael Goller
Independent Director
-
2025
Gross Remuneration
Year

Replimune Group Inc FAQ

How is Replimune Group Inc today?
Replimune Group Inc today is trading in the green, and is up by 9.50% at 8.76.
Replimune Group Inc is currently trading up 9.50% on an intraday basis. In the past week the stock rose 19.18%. stock has been down -13.61% in the past quarter and rose 35.81% in the past year. You can view this in the overview section.